GoodRx (NASDAQ:GDRX) Price Target Lowered to $15.00 at Barclays

GoodRx (NASDAQ:GDRX – Get Rating) had its price objective decreased by investment analysts at Barclays from $28.00 to $15.00 in a research note issued on Tuesday, The Fly reports. Barclays‘s price objective indicates a potential upside of 39.53% from the stock’s current price.

A number of other research firms have also weighed in on GDRX. Raymond James lowered shares of GoodRx from an “outperform” rating to a “market perform” rating in a research note on Tuesday. The Goldman Sachs Group decreased their target price on shares of GoodRx from $43.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, March 1st. Zacks Investment Research raised shares of GoodRx from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 3rd. Bank of America decreased their target price on shares of GoodRx from $42.00 to $28.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 1st. Finally, SVB Leerink lowered shares of GoodRx from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $33.00 to $10.00 in a research note on Tuesday. One analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, GoodRx presently has a consensus rating of “Hold” and an average price target of $26.72.

GDRX stock opened at $10.75 on Tuesday. The company has a current ratio of 13.42, a quick ratio of 13.42 and a debt-to-equity ratio of 0.79. GoodRx has a 12-month low of $10.65 and a 12-month high of $48.05. The stock has a market cap of $4.31 billion, a price-to-earnings ratio of -153.55, a PEG ratio of 4.42 and a beta of 0.29. The business’s 50-day moving average is $16.74 and its 200 day moving average is $27.69.

GoodRx (NASDAQ:GDRX – Get Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.02. GoodRx had a positive return on equity of 0.06% and a negative net margin of 3.39%. The company had revenue of $203.30 million for the quarter, compared to analysts’ expectations of $200.61 million. During the same period in the previous year, the firm posted ($0.01) EPS. GoodRx’s revenue was up 26.7% compared to the same quarter last year. As a group, equities analysts forecast that GoodRx will post 0.17 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of GDRX. Deutsche Bank AG increased its holdings in GoodRx by 65.6% in the 3rd quarter. Deutsche Bank AG now owns 40,006 shares of the company’s stock valued at $1,641,000 after purchasing an additional 15,850 shares during the last quarter. Commerce Bank acquired a new stake in GoodRx in the 3rd quarter valued at approximately $615,000. First Horizon Advisors Inc. increased its holdings in GoodRx by 208.2% in the 3rd quarter. First Horizon Advisors Inc. now owns 1,350 shares of the company’s stock valued at $42,000 after purchasing an additional 912 shares during the last quarter. CIBC Asset Management Inc increased its holdings in GoodRx by 9.5% in the 3rd quarter. CIBC Asset Management Inc now owns 15,748 shares of the company’s stock valued at $646,000 after purchasing an additional 1,369 shares during the last quarter. Finally, US Bancorp DE increased its holdings in GoodRx by 6.3% in the 3rd quarter. US Bancorp DE now owns 116,740 shares of the company’s stock valued at $4,788,000 after purchasing an additional 6,899 shares during the last quarter. Hedge funds and other institutional investors own 52.60% of the company’s stock.

GoodRx Company Profile (Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Featured Stories